Literature DB >> 20922511

Impact of seropositivity to Chlamydia pneumoniae and anti-hHSP60 on cardiovascular events in hemodialysis patients.

Pasquale Esposito1, Carmine Tinelli, Carmelo Libetta, Elisa Gabanti, Teresa Rampino, Antonio Dal Canton.   

Abstract

Autoimmunity to heat shock protein 60 (HSP60) has been related to atherosclerosis. Chlamydia pneumoniae (CP), the most studied infectious agent implicated in promoting atherosclerosis, produces a form of HSP60, which can induce an autoimmune response, due to high antigenic homology with human HSP60 (hHSP60). In this study, we evaluated the correlations among anti-hHSP60 antibodies, CP infection, and cardiovascular disease (CVD) in a high-risk population, such as patients undergoing hemodialysis (HD). Thirty-two patients (67.9 ± 13.9 years; male/female, 23:9) on regular HD were enrolled. Global absolute cardiovascular risk (GCR) was assessed using the Italian CUORE Project's risk charts, which evaluate age, gender, smoking habits, diabetes, systolic blood pressure, and serum cholesterol. The occurrence of cardiovascular events during a 24-month follow-up was recorded. Seropositivity to CP and the presence of anti-hHSP60 antibodies were tested by specific enzyme-linked immunosorbent assays. Inflammation was assessed by measurement of C-reactive protein (CRP) serum levels. Fifteen healthy sex and age-matched (61.9 ± 9.5 years; male/female, 11:4) subjects were the control group. Fifteen of 32 patients resulted seropositive for CP. CP + patients were older than CP-, while they did not differ for GCR, CRP, and dialytic parameters. CVD incidence was significantly higher in CP+ (9 CP+ vs 2 CP-, p < 0.05). Cox analysis recognized that the incidence of CVD was independently correlated with seropositivity to CP (HR, 7.59; p = 0.01; 95% CI = 1.63-35.4). On the other hand, there were no significant differences in anti-hHSP60 levels among CP+, CP- and healthy subjects: 18.11 μg/mL (14.8-47.8), 31.4 μg/mL (23.2-75.3), and 24.72 μg/mL (17.7-41.1), respectively. Anti-hHSP60 did not correlate to GCR, CRP, and incidence of CVD. In conclusion, our data suggest that anti-hHSP60 autoimmune response is not related to CP infection and CP-related CVD risk in HD patients.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20922511      PMCID: PMC3059795          DOI: 10.1007/s12192-010-0235-5

Source DB:  PubMed          Journal:  Cell Stress Chaperones        ISSN: 1355-8145            Impact factor:   3.667


  41 in total

1.  Prediction of coronary events in a low incidence population. Assessing accuracy of the CUORE Cohort Study prediction equation.

Authors:  Marco Ferrario; Paolo Chiodini; Lloyd E Chambless; Giancarlo Cesana; Diego Vanuzzo; Salvatore Panico; Roberto Sega; Lorenza Pilotto; Luigi Palmieri; Simona Giampaoli
Journal:  Int J Epidemiol       Date:  2005-01-19       Impact factor: 7.196

2.  Dual role of infections as risk factors for coronary heart disease.

Authors:  Erkki Pesonen; Eva Andsberg; Hans Ohlin; Mirja Puolakkainen; Hilpi Rautelin; Seppo Sarna; Kenneth Persson
Journal:  Atherosclerosis       Date:  2006-06-15       Impact factor: 5.162

3.  Chlamydia pneumoniae antibody levels before coronary events in the Helsinki Heart Study as measured by different methods.

Authors:  Mika Paldanius; Maija Leinonen; Hanna Virkkunen; Leena Tenkanen; Tiina Sävykoski; Matti Mänttäri; Pekka Saikku
Journal:  Diagn Microbiol Infect Dis       Date:  2006-06-06       Impact factor: 2.803

Review 4.  Disturbances of acquired immunity in hemodialysis patients.

Authors:  Theodoros Eleftheriadis; Georgia Antoniadi; Vassilios Liakopoulos; Charalambos Kartsios; Ioannis Stefanidis
Journal:  Semin Dial       Date:  2007 Sep-Oct       Impact factor: 3.455

5.  Acute Chlamydia pneumoniae infection with heat-shock-protein-60-related response in patients with acute coronary syndrome.

Authors:  Shiro Hoshida; Masami Nishino; Jun Tanouchi; Toshio Kishimoto; Yoshio Yamada
Journal:  Atherosclerosis       Date:  2005-03-24       Impact factor: 5.162

6.  Chlamydia pneumoniae infection and ischemic heart disease in hemodialysis patients.

Authors:  M Wszola; A Kwiatkowski; R Nosek; E Podsiadly; J Meszaros; R Danielewicz; W Lisik; K Ostrowski; A Chmura; L Adadyński; L Paczek; M Durlik; S Tylewska-Wierzbanowska; W Rowiński
Journal:  Transplant Proc       Date:  2006 Jan-Feb       Impact factor: 1.066

7.  Association between seroprevalence of anti-chlamydial antibodies and long-term cardiovascular mortality in chronic hemodialysis patients.

Authors:  Akihiko Kato; Takako Takita; Mitsuyoshi Furuhashi; Yukitaka Maruyama; Akira Hishida
Journal:  Atherosclerosis       Date:  2005-11-08       Impact factor: 5.162

8.  Implications of antibodies to heat-shock proteins in ischemic heart disease.

Authors:  Vicky Y Hoymans; Johan M Bosmans; Paul L Van Herck; Margareta M Ieven; Christiaan J Vrints
Journal:  Int J Cardiol       Date:  2007-03-26       Impact factor: 4.164

9.  Associations of serologic markers of infection and inflammation with vascular disease events and mortality in American dialysis patients.

Authors:  Krista L Lentine; Julie Parsonnet; Isabella Taylor; Elizabeth M Wrone; Richard A Lafayette
Journal:  Clin Exp Nephrol       Date:  2006-03       Impact factor: 2.801

10.  Uremia impairs monocyte and monocyte-derived dendritic cell function in hemodialysis patients.

Authors:  W H Lim; S Kireta; E Leedham; G R Russ; P T Coates
Journal:  Kidney Int       Date:  2007-08-29       Impact factor: 10.612

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.